Simulation of the economic impact of introducing rivaroxaban in a high-complexity hospital for venous thromboembolism prophylaxis

Authors

DOI:

https://doi.org/10.30968/rbfhss.2024.153.1153

Abstract

Objective: this work aims to simulate the economic impact of the introduction of rivaroxaban for venous thromboembolism (VTE) prophylaxis, when compared to the therapeutic options used in the institution (unfractionated heparin and enoxaparin), in the period from January to February 2022. Methods: In a retrospective study, we analyzed the possibility of replacing the prophylaxis used in the institution with prophylaxis with rivaroxaban based on the analysis of data from the electronic medical record system, taking into account the length of stay, the medications prescribed and compliance with the institutional protocol. Patients prescribed medication for VTE prophylaxis and indicated according to progress in the medical record were included, excluding those using non-pharmacological prophylaxis. Patients with contraindications to the use of rivaroxaban, such as pregnancy and liver impairment, were also excluded. Monte Carlo Simulation was used to calculate the cost of treatment with DOACs (Direct Oral Anticoagulants), using the medicines acquisition values during the study period, and a decision tree was constructed. Results: A total of 157 patients who were prescribed one of the heparins were evaluated. Of these patients, 98 (62.4%) could undergo prophylaxis with rivaroxaban as they had no contraindication to this treatment (price recorded in January/February 2022: R$ 0.23). This new prophylaxis would generate savings of up to 98.4% for enoxaparin 40 mg (price recorded in January/February: R$ 14.26), the item that had the highest consumption, corresponding to 71.4% of patients who could use it rivaroxaban. Conclusion: The implementation of rivaroxaban for venous thromboembolism prophylaxis replacing enoxaparin proved to be beneficial in terms of costs for the hospital, which suggests that more studies should be carried out in order to increase the robustness of results and support the incorporation of this technology in the institution.

Downloads

Download data is not yet available.

References

Burihan MC, et al. Consenso e atualização na profilaxia e no tratamento do tromboembolismo venoso. 1.ed. Rio de Janeiro: Guanabara Koogan, 2019.

Bauer KA, Lip GH. Overview of the causes of venous thrombosis. UpToDate. Disponível em: https://www.uptodate.com/contents/over-view-of-the-causes-of-venous-thrombosis?search=tromboembolismo%20venoso&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1. Acesso em: 20 maio 2023.

Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of Venous Thromboembolism. Chest, 2008;133(6):63. DOI:10.1378/chest.08-0656.

Dobesh PP, Fanilos J. New Oral Anticoagulants for the Treatment of Venous Thromboembolism: understanding differences and similarities. Drugs. Spr Sci and Bus Media LLC. 2014;74(17):17. DOI:10.1007/s40265-014-0301-x.

Hull, RD, Garcia DA; Burnett, AE. Heparin and LMW heparin: Dosing and adverse effects. UpToDate. Disponível em: https://www.uptodate.com/contents/heparin-and-lmw-heparin-dosing-and-adverse-effects?topicRef=1370&source=see_link#H437372. Acesso em: 30 maio 2023

Linchtenstein A, et al. Tromboembolismo venoso (TEV). Protocolo Institucional do Instituto Central do Hospital das Clínicas da Faculdade de Medicina da USP de São Paulo, versão 2, 15 mar. 2022.

Cohen, AT et al. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis. PLoS One. 2015; 10(12). DOI: 10.1371/journal.pone.0144856.

Key NS, Bohlke K, Falanga A. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: asco clinical practice guideline update summary. J Onc Pract. 2019;15(12):5. DOI:10.1200/jop.19.00368.

Brasil. Agência Nacional de Vigilância Sanitária (ANVISA). Bulário Eletrônico. Disponível em: https://consultas.anvisa. gov.br/#/bulario/. Acesso em: 28 maio 2023.

Lin S, Wang Y, Zhang L, et al. Dabigatran must be used carefully: literature review and recommendations for management of adverse events. Drug Dsg, Develop And Therapy. 2019;13:8. DOI:10.2147/dddt.s203112.

Diamantopoulos A, Lees M, Weels PS, et al. Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada. Thromb And Haemos. 2010;104(10):12. DOI: 10.1160/th10-01-0071.

Ghanima W, Atar D, Sandset PM. Nye perorale antikoagulasjonsmidler – en oversikt. Tids For Den Nor Legeforening. 2013;133(18):6. DOI: 10.4045/tidsskr.12.1111.

Brasil. Ministério da Saúde. Secretaria de Ciência, tecnologia e insumos estratégicos. Diretrizes metodológicas: Diretriz de avaliação econômica. Brasília, 2014.

Maia LM. et al. A importância da ferramenta curva ABC no gerenciamento de estoque [artigo]. Anais do IX Simpósio de Engenharia de Produção de Sergipe. São Cristóvão, 2017.

BRASIL. Lei nº 14133, de 01 de abril de 2021. Lei de Licitações e Contratos Administrativos. 61-F. ed. Brasília, DF: Diário Oficial da União, 01 abr. 2021. Seção 1.

Paula RR. Método de Monte Carlo e aplicações [monografia]. Universidade Federal Fluminense, Volta Redonda – RJ, 2014. Disponível em: https://app.uff.br/riuff/handle/1/4180. Acesso em: 07 abril 2024.

Velaz OA, Bueno, IC. Rivaroxaban frente a enoxaparina como tromboprofilaxis em cirugía ortopédica y traumatología: um metaanálisis. Rev Esp Cir Ortop Traumatol. 2023:11. DOI: 10.1016/j.recot.2023.09.005

Gulati S, Eckman MH. Anticoagulant Therapy for Cancer-Associated Thrombosis : A Cost-Effectiveness Analysis. Ann Intern Med. 2023;176(1):9. DOI: 10.7326/M22-1258

Xu J, Chang D, Chui J, et al. The efficacy and cost-effectiveness of enoxaparin versus rivaroxaban in the prevention of venous thromboembolism following total hip or knee arthroplasty: A meta-analysis. J Orthop. 2022;30:6. DOI: 10.1016/j.jor.2022.02.003

Published

2024-07-11

How to Cite

1.
DE CARVALHO DS, DE SOUZA RA, SFORSIN AC, PINTO VB, MARTINS MC, CHAVES CE. Simulation of the economic impact of introducing rivaroxaban in a high-complexity hospital for venous thromboembolism prophylaxis. Rev Bras Farm Hosp Serv Saude [Internet]. 2024Jul.11 [cited 2024Dec.11];15(3):e1153. Available from: https://www.rbfhss.org.br/sbrafh/article/view/1153

Issue

Section

ORIGINAL ARTICLES